132 related articles for article (PubMed ID: 18223510)
1. [Dyslipidemia and abdominal obesity: mechanisms and characteristics (Part I)].
Farnier M
Arch Mal Coeur Vaiss; 2007 Dec; 100(12):979-84. PubMed ID: 18223510
[TBL] [Abstract][Full Text] [Related]
2. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
Rader DJ
Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
[TBL] [Abstract][Full Text] [Related]
3. Obesity and atherogenic dyslipidemia.
Bamba V; Rader DJ
Gastroenterology; 2007 May; 132(6):2181-90. PubMed ID: 17498511
[TBL] [Abstract][Full Text] [Related]
4. Obesity and dyslipidemia.
Franssen R; Monajemi H; Stroes ES; Kastelein JJ
Med Clin North Am; 2011 Sep; 95(5):893-902. PubMed ID: 21855698
[TBL] [Abstract][Full Text] [Related]
5. [Android-type obesity and gynecoid-type obesity].
Janjic D
Praxis (Bern 1994); 1996 Dec; 85(49):1578-83. PubMed ID: 8992575
[TBL] [Abstract][Full Text] [Related]
6. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
[TBL] [Abstract][Full Text] [Related]
7. Adipose tissue dysfunction in obesity.
Blüher M
Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):241-50. PubMed ID: 19358089
[TBL] [Abstract][Full Text] [Related]
8. Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue.
Lafontan M; Girard J
Diabetes Metab; 2008 Sep; 34(4 Pt 1):317-27. PubMed ID: 18550411
[TBL] [Abstract][Full Text] [Related]
9. Impact of visceral adipose tissue on liver metabolism and insulin resistance. Part II: Visceral adipose tissue production and liver metabolism.
Girard J; Lafontan M
Diabetes Metab; 2008 Nov; 34(5):439-45. PubMed ID: 18562233
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers.
Toh SA; Rader DJ
Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):1007-22. PubMed ID: 18666851
[TBL] [Abstract][Full Text] [Related]
11. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
Chapman MJ; Sposito AC
Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
[TBL] [Abstract][Full Text] [Related]
12. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association.
Bays HE; Toth PP; Kris-Etherton PM; Abate N; Aronne LJ; Brown WV; Gonzalez-Campoy JM; Jones SR; Kumar R; La Forge R; Samuel VT
J Clin Lipidol; 2013; 7(4):304-83. PubMed ID: 23890517
[TBL] [Abstract][Full Text] [Related]
13. The clinical biochemistry of obesity-more than skin deep.
Sikaris KA
Heart Lung Circ; 2007; 16 Suppl 3():S45-50. PubMed ID: 17611153
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.
Bays HE; González-Campoy JM; Bray GA; Kitabchi AE; Bergman DA; Schorr AB; Rodbard HW; Henry RR
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):343-68. PubMed ID: 18327995
[TBL] [Abstract][Full Text] [Related]
15. Adipokines--targeting a root cause of cardiometabolic risk.
Bakhai A
QJM; 2008 Oct; 101(10):767-76. PubMed ID: 18550581
[TBL] [Abstract][Full Text] [Related]
16. The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors.
Quijada Z; Paoli M; Zerpa Y; Camacho N; Cichetti R; Villarroel V; Arata-Bellabarba G; Lanes R
Pediatr Diabetes; 2008 Oct; 9(5):464-71. PubMed ID: 18507788
[TBL] [Abstract][Full Text] [Related]
17. [Dyslipidemia and abdominal obesity: therapeutic approaches (Part II)].
Farnier M
Arch Mal Coeur Vaiss; 2007 Dec; 100(12):985-7, 990-1. PubMed ID: 18223511
[TBL] [Abstract][Full Text] [Related]
18. Visceral obesity, insulin resistance, and dyslipidemia: contribution of endurance exercise training to the treatment of the plurimetabolic syndrome.
Després JP
Exerc Sport Sci Rev; 1997; 25():271-300. PubMed ID: 9213095
[No Abstract] [Full Text] [Related]
19. Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood: the Cardiovascular Risk in Young Finns Study.
Juonala M; Viikari JS; Rönnemaa T; Marniemi J; Jula A; Loo BM; Raitakari OT
Arterioscler Thromb Vasc Biol; 2008 May; 28(5):1012-7. PubMed ID: 18309111
[TBL] [Abstract][Full Text] [Related]
20. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M; Olofsson SO; Taskinen MR; Borén J
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
